Рет қаралды 14,798
RF Longevity Founder Gary Arendash talks immunity, cytokines and increasing human longevity through bioengineering with FDA breakthrough tech.
Fourteen years ago, scientists discovered exposing transgenic mice with Alzheimer’s to RF waves produced some exciting results; not only were the mice protected from further cognitive decline, but older mice even experienced a reversal of cognitive impairment. It will come as no surprise that the researchers set about leveraging this tech for a human approach, developing a treatment called Transcranial Radiofrequency Wave Treatment (TRFT). RF Longevity has realized this therapy in a device called MemorEM, a patented, noninvasive technology that has received Breakthrough Device designation from the US FDA as a potential treatment for Alzheimer’s in humans.
The MemorEM device delivers radiofrequency waves to the brain via eight transmitters embedded in a cap and a control box worn on the arm. Users wear the device at home for an hour a day, and experience no sound or sensation associated with the device - they can pretty much get on with anything during this time, although perhaps not grab a shower!
We sat down with Dr Gary Arendash, founder of RF Longevity, to find out more about MemorEM's potential for Alzheimer's therapy and lifespan extension and why all roads for a life extending intervention must go through preventing or lessening dementia.
---------------------------
Visit Longevity.Technology - bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - bit.ly/3AMIXuq
Facebook - bit.ly/3z8H1v5
Instagram - bit.ly/3IDvVRX
LinkedIn - bit.ly/3yIfDmf
More about RF Longevity: rflongevity.com/